
Revvity, Inc.
RVTY · Healthcare · Life Sciences Tools & Services
Updated 24 min ago · data delayed ≥15 min
IconicScore
ProprietaryRanked #426 of 500 by Iconic Score · #49 of 59in its sector. IconicAlpha’s proprietary brand-intelligence metric — a multi-model blend of scale, market attention, category leadership, and AI-analyzed brand visibility.
Get the free morning email
The biggest IconicScore™ gainer and loser, plus the strongest and weakest sectors, in your inbox before the open. See a sample →
Price performance
Export history · AnalystThis insight is part of the Analyst tier — unlock the IconicScore vs. price overlay, side-by-side comparison, and CSV export.
Upgrade to AnalystThis is part of the Enterprise tier — benchmark your IconicScore against sector peers, claim your profile, and manage how your brand appears on the wall.
Upgrade to EnterpriseIconic Profile
Revvity Inc (RVTY) is a leading provider of life sciences tools and services, specializing in innovative solutions that enhance research and development in the healthcare sector. With a market capitalization of $12.3 billion, Revvity leverages advanced technologies to streamline drug discovery, improve clinical trials, and accelerate the development of therapeutics. The company is positioned at the forefront of the life sciences industry, offering a comprehensive suite of products that support researchers and organizations in their pursuit of scientific breakthroughs. Revvity's commitment to advancing healthcare through technology not only enhances operational efficiencies but also contributes to the overall improvement of patient outcomes, making it a significant player in the evolving landscape of life sciences.
IconicOracleAI™ Brief
Revvity Inc (RVTY) currently holds an Iconic Score of 35, reflecting moderate brand recognition amid a market cap of $17.5B. The recent launch of the Signals LabGistics Solution has garnered attention, enhancing its visibility in the scientific workflow space, as indicated by a brand-visibility signal of 75/100. However, the overall sentiment remains cautious, as highlighted by mixed discussions in recent headlines regarding the company’s positioning in the AI drug discovery sector.
AI-generated explanation of current score drivers. Not investment advice.
Enterprise tier: claim your logo to manage how your brand is represented.